Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ET140202 |
Synonyms | |
Therapy Description |
ET140202 consists of autologous T-cells engineered to express a T-cell receptor mimetic antibody that recognizes alpha-fetoprotein (AFP) combined with HLA-A02, which may result in antitumor activity of cells expressing AFP (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ET140202 | ET-140202 | ET140202 consists of autologous T-cells engineered to express a T-cell receptor mimetic antibody that recognizes alpha-fetoprotein (AFP) combined with HLA-A02, which may result in antitumor activity of cells expressing AFP (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03998033 | Phase Ib/II | ET140202 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma | Terminated | USA | 0 |